OncoSec Medical Inc (ONCSQ)

[Titan V]

It seems the NCI is planning a phase 1 trial using IL-12 + Keytruda on solid tumors later this year.
https://clinicaltrials.gov/ct2/show/NCT03030378?term=il-12+keytruda&rank=1

This phase I trial studies the side effects and best dose of pembrolizumab and recombinant interleukin-12 in treating patients with solid tumors. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Recombinant interleukin-12 may kill tumor cells by blocking blood flow to the tumor and by stimulating white blood cells to kill tumor cells. Giving pembrolizumab and recombinant interleukin-12 may work better in treating patients with solid tumors.

(Unrelated to ONCS. Just thought it was interesting and relevant due to the use of IL-12 with Keytruda.)